anti-GPRC5D/anti-CD19 CAR T cells

A preparation of T lymphocytes engineered to express chimeric antigen receptor(s) (CARs) targeting the human tumor-associated antigens (TAAs) G-protein coupled receptor family C group 5 member D (GPRC5D) and CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPRC5D/anti-CD19 CAR T cells specifically and simultaneously target and bind to tumor cells expressing GPRC5D and/or CD19. This induces selective toxicity in tumor cells that express GPRC5D and/or CD19. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies.